| Literature DB >> 35455092 |
Razvan Anghel1,2, Cristina Andreea Adam1, Dragos Traian Marius Marcu2, Ovidiu Mitu2,3, Mihai Roca1,2, Grigore Tinica4,5, Florin Mitu1,2.
Abstract
Background andEntities:
Keywords: adherence; ambulatory arterial stiffness index; arterial stiffness; cardiac rehabilitation; exercise; peripheral artery disease; quality of life
Year: 2022 PMID: 35455092 PMCID: PMC9024562 DOI: 10.3390/life12040601
Source DB: PubMed Journal: Life (Basel) ISSN: 2075-1729
Figure 1Flow chart of the studied group (IC: intermittent claudication; ABI: ankle-brachial index; PAD: peripheral artery disease; ABPM: ambulatory blood pressure monitoring).
Demographics and resting hemodynamics.
| Parameter | Initial Evaluation | 6-Month Follow-Up | |
|---|---|---|---|
|
| |||
| Height, cm | 171.44 ± 8.77 | - | |
| Weight, kg | 83.72 ± 15.49 | 73.08 ± 13.52 | 0.708 |
| Body mass index, kg/m2 | 27.74 ± 3.65 | 24.14 ± 3.17 | 0.037 |
|
| |||
| Heart rate, bpm | 72.71 ± 12.28 | 68.55 ± 11.98 | 0.096 |
| Systolic BP, mmHg | 140.79 ± 21.56 | 134.73 ± 20.63 | 0.131 |
| Diastolic BP, mmHg | 80.15 ± 14.97 | 77.26 ± 14.43 | 0.485 |
|
| 69 (71.1%) | 51 (52.6%) | 0.032 |
|
| |||
| Active or in the past | 63 (64.9%) | 29 (29.9%) | <0.001 |
|
| 16 (16.5%) | 9 (9.3%) | 0.973 |
All values are expressed as mean ± standard deviation (SD) or n (%); bpm: beats per minute; BP: blood pressure.
Comorbidities and clinical examination.
| Parameter | 6-Month Follow-Up ( | No Clinical Improvement after CR Program ( | With Clinical Improvement after CR ( | |
|---|---|---|---|---|
|
| ||||
| Hypertension | 61 (62.9%) | 20 (90.9%) | 41 (54.7%) | 0.002 |
| Diabetes mellitus | 56 (57.7%) | 19 (86.4%) | 37 (49.3%) | 0.002 |
| Dyslipidemia | 57 (58.8%) | 17 (77.3%) | 40 (53.3%) | 0.045 |
| Obesity | 61 (62.9%) | 15 (68.2%) | 46 (61.3%) | 0.564 |
| Coronary artery disease | 48 (49.5%) | 13 (59.1%) | 35 (46.7%) | 0.310 |
| Heart failure | 70 (72.2%) | 18 (81.8%) | 52 (69.3%) | 0.255 |
| COPD | 14 (14.4%) | 6 (27.3%) | 8 (10.7%) | 0.052 |
| Chronic kidney disease | 53 (54.6%) | 10 (45.5%) | 43 (57.3%) | 0.330 |
|
| ||||
| Paresthesia | 43 (44.3%) | 4 (18.2%) | 39 (52.0%) | 0.005 |
| Feeling of cold feet | 51 (52.6%) | 5 (22.7%) | 46 (61.3%) | 0.001 |
| Pale skin | 35 (36.1%) | 9 (40.9%) | 26 (34.7%) | 0.596 |
| Cold skin | 32 (33.0%) | 3 (13.6%) | 29 (38.7%) | 0.028 |
| Reduced pilosity | 32 (33.0%) | 4 (18.2%) | 28 (37.3%) | 0.254 |
| Subcutaneous atrophy | 21 (21.6%) | 2 (9.1%) | 19 (25.3%) | 0.106 |
| Thickened nails | 22 (22.7%) | 3 (13.6%) | 19 (25.3%) | 0.254 |
| Petechiae | 21 (21.6%) | 4 (18.2%) | 17 (22.7%) | 0.657 |
| Arterial ulcers | 5 (5.2%) | 1 (4.5%) | 4 (5.3%) | 0.885 |
| Dermatitis | 12 (12.4%) | 3 (13.6%) | 9 (12.0%) | 0.840 |
|
| 29 (29.9%) | 15 (68.2%) | 61 (81.3%) | <0.001 |
|
| 51 (52.6%) | 16 (72.7%) | 35 (46.7%) | 0.032 |
All values are expressed as n (%). COPD: chronic obstructive pulmonary disease.
Blood biochemistry and exercise stress test parameters.
| Parameter | Before CR | 6-Month Follow-Up ( | With Clinical Improvement after CR ( | No Clinical Improvement after CR Program ( | |
|---|---|---|---|---|---|
|
| |||||
| Total cholesterol, mg/dL | 206.95 ± 75.90 | 172.92 ± 63.12 | 167.95 ± 58.19 | 189.88 ± 76.76 | 0.153 |
| LDL-cholesterol, mg/dL | 135.40 ± 67.79 | 121.86 ± 61.01 | 112.43 ± 43.58 | 154.02 ± 94.47 | 0.004 |
| HDL-cholesterol, mg/dL | 42.84 ± 16.92 | 44.56 ± 17.60 | 44.08 ± 18.66 | 46.18 ± 13.63 | 0.625 |
| Triglycerides, mg/dL | 185.27 ± 122.13 | 161.18 ± 106.26 | 145.10 ± 61.93 | 216.01 ± 184.46 | 0.005 |
| CRP, mg/dL | 5.33 ± 14.30 | 3.42 ± 5.07 | 2.87 ± 2.77 | 5.30 ± 9.26 | 0.047 |
| HbA1C, g% | 7.96 ± 2.23 | 7.64 ± 2.14 | 6.71 ± 1.35 | 10.75 ± 1.16 | <0.001 |
| Fasting glucose, mg/dL | 153.94 ± 63.54 | 146.51 ± 64.19 | 132.65 ± 43.85 | 193.13 ± 94.89 | <0.001 |
|
| |||||
| VO2 peak mL/kg/min | 12.34 ± 4.74 | 14.31 ± 4.74 | 14.95 ± 5.74 | 12.13 ± 3.94 | 0.034 |
| Peak HR, bpm | 118.61 ± 18.81 | 131.66 ± 20.88 | 132.66 ± 21.54 | 128.25 ± 18.48 | 0.386 |
| Peak systolic BP, mmHg | 171.52 ± 27.03 | 157.17 ± 19.78 | 154.94 ± 18.11 | 164.76 ± 23.55 | 0.040 |
| Peak diastolic BP, mmHg | 90.54 ± 13.31 | 88.73 ± 13.04 | 89.40 ± 13.46 | 86.46 ± 11.50 | 0.356 |
| RER | 1.07 ± 0.10 | 1.09 ± 0.10 | 1.076 ± 0.10 | 1.070 ± 0.10 | 0.820 |
| Borg scale | 15.45 ± 1.58 | 13.31 ± 1.14 | 13.12 ± 1.02 | 13.95 ± 1.29 | 0.002 |
|
| 0.65 ± 0.21 | 0.66 ± 0.23 | 0.84 ± 0.25 | 0.71 ± 0.24 | 0.031 |
|
| 246.43 ± 185.49 | 274.96 ± 175.52 | 291.33 ± 174.87 | 219.15 ± 169.84 | 0.046 |
|
| |||||
| LVEF, % | 46.41 ± 9.74 | 49.37 ± 10.43 | 50.93 ± 9.93 | 44.03 ± 10.55 | 0.006 |
|
| |||||
| Systolic BP | 143.60 ± 21.99 | 135.42 ± 20.74 | 129.67 ± 15.52 | 138.27 ± 19.58 | 0.034 |
| Diastolic BP | 81.59 ± 15.24 | 77.59 ± 14.50 | 71.40 ± 11.32 | 79.28 ± 15.17 | 0.009 |
| Pulse pressure | 81.59 ± 15.24 | 77.59 ± 14.50 | 58.65 ± 11.54 | 51.62 ± 12.19 | 0.024 |
| AASI | 0.52 ± 0.18 | 0.46 ± 0.12 | 0.42 ± 0.19 | 0.47 ± 0.11 | 0.008 |
All values are expressed as mean ± standard deviation (SD). LDL-cholesterol: low-density lipoprotein cholesterol, HDL-cholesterol: high-density lipoprotein cholesterol; CRP: C reactive protein; HbA1C: glycated hemoglobin; VO2 peak: peak oxygen uptake; bpm: beats per minute; HR: heart rate; BP: blood pressure; RER: respiratory exchange ratio; ABI: ankle-brachial index; LVEF: left ventricle ejection fraction; AASI: ambulatory arterial stiffness index.
Figure 2Parameters associated with clinical improvement at the 6-month follow-up. (HbA1C: glycated hemoglobin; LDL-cholesterol: low-density lipoprotein cholesterol, ABI: ankle-brachial index).
Predictors of clinical improvement at the 6-month follow-up.
| Logistic Regression | |||
|---|---|---|---|
| Parameter | OR | 95% CI | |
| Decreasing fasting glucose by at least 7% | 0.986 | 0.001 | 0.978–0.995 |
| Decreasing of HbA1C by at least 4% | 1.097 | 0.001 | 1.039–1.159 |
| Changing sedentary lifestyle | 0.328 | 0.036 | 0.116–0.930 |
| Ceasing smoking | 0.107 | <0.001 | 0.037–0.312 |
| Improvement of paresthesia | 4.875 | 0.008 | 1.507–15.775 |
| Improvement of feeling of cold feet | 5.393 | 0.003 | 1.795–16.204 |
| Improvement of cold skin | 3.993 | 0.037 | 1.085–14.699 |
| Decreasing LDL–cholesterol by at least 10% | 0.989 | 0.013 | 0.981–0.998 |
| Decreasing triglycerides by at least 13% | 0.994 | 0.026 | 0.988–0.999 |
| Increasing of ABI value | 10.753 | 0.034 | 1.196–96.685 |
| Increasing Borg Scale score | 0.446 | 0.004 | 0.259–0.769 |
| Increasing of VO2peak mL/kg/min | 1.138 | 0.040 | 1.006–1.287 |
| Decreasing of peak systolic BP, mmHg | 0.974 | 0.045 | 0.949–0.999 |
| Improvement of pulse pressure | 0.954 | 0.028 | 0.915–0.995 |
| Improvement of AASI | 1.127 | 0.021 | 1.069–1.105 |
CI: Confidence interval; OR: Odds ratio; HbA1C: glycated hemoglobin; LDL-cholesterol: low-density lipoprotein cholesterol; ABI: ankle-brachial index; VO2 peak: peak oxygen uptake; BP: blood pressure; AASI: ambulatory arterial stiffness index.
Figure 3The receiver operating characteristic curve of the clinical signs and ABI value associated with clinical improvement (ABI: ankle-brachial index).